The SCLC-P subtype group showed high expression levels of TIM3, OX40, OX40L, galectin9 and MHC-II on TILs, indicating that patients with the SCLC-P subtype might benefit from treatment with TIM3, OX40, OX40L, galectin9 or MHC-II inhibitors (Figure S2). Here, TNFRSF4 is linked to small cell lung carcinoma.